Sage Journals: Discover world-class research

Abstract

Background:

No randomized controlled trials have compared the efficacy of fingolimod or natalizumab as second-line treatment in patients with relapsing–remitting multiple sclerosis (RRMS).

Objective:

To compare clinical outcomes after escalation to fingolimod versus natalizumab in patients with clinically active RRMS.

Methods:

Using the registry of the Swiss Federation for Common Tasks of Health Insurances, we identified patients with RRMS and ≥1 relapse in the year before switching from interferon beta or glatiramer acetate to fingolimod or natalizumab. Propensity score matching was used to select patients with comparable baseline characteristics. Relapse and Expanded Disability Status Scale (EDSS) outcomes were compared in paired, pairwise-censored analyses.

Results:

Of the 547 included patients, 358 were matched (fingolimod, n = 179; natalizumab, n = 179). Median follow-up time was 1.8 years (interquartile range 0.9–2.9). Patients switching to natalizumab had a lower risk of relapses (incidence rate ratio 0.5, 95% confidence interval (CI) 0.3–0.8, p = 0.001) and were more likely to experience EDSS improvement (hazard ratio (HR) 1.8, 95% CI 1.1–2.7, p = 0.01) compared to fingolimod. We found no differences in the proportion of patients free from EDSS progression (HR 0.9, 95% CI 0.5–1.5, p = 0.62).

Conclusion:

Natalizumab seems to be more effective in reducing relapse rate and improving disability compared with fingolimod.

Keywords

Multiple sclerosis natalizumab fingolimod observational study relapse rate disability progression

Get full access to this article

View all access options for this article.

References

Polman

O’Connor

Havrdova

et al . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Kappos

Radue

O’Connor

et al . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Calabresi

Radue

Goodin

et al . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545–556.

Rudick

Stuart

Calabresi

et al . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

Cohen

Barkhof

Comi

et al . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Spelman

Kalincik

Zhang

et al . Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol 2015; 2: 479–491.

Spelman

Jokubaitis

et al . Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol 2015; 72: 405–413.

Comi

Radaelli

Soelberg Sorensen

Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 2016; 389: 1347–1356.

European Medicines Agency. Tysabri (natalizumab): Summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf (accessed 2 December 2016).

10.

European Medicines Agency. Gilenya (fingolimod): Summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf (accessed 2 December 2016).

11.

Swissmedic.Tysabri 300 mg, Konzentrat zur Herstellung einer Infusionslösung (natalizumab), https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/tysabri-300mg–konzentrat-zur-herstellung-einer-infusionsloesung.html (accessed 2 December 2016).

12.

Swissmedic. Gilenya, Kapseln (fingolimod), https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/gilenya—kapseln–fingolimod-.html (accessed 2 December 2016).

13.

U.S. National Library of Medicine. Impact of natalizumab versus fingolimod in relapsing-remitting multiple sclerosis (RRMS) participants (REVEAL). Identifier NCT02342704. Bethesda, MD: U.S. National Library of Medicine, https://clinicaltrials.gov/ct2/show/NCT02342704 (accessed 30 November 2016).

14.

Rosenbaum

Rubin

DB.

Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516–524.

15.

Kalincik

Butzkueven

Observational data: Understanding the real MS world. Mult Scler 2016; 22: 1642–1648.

16.

Trojano

Tintore

Montalban

et al . Treatment decisions in multiple sclerosis—Insights from real-world observational studies. Nat Rev Neurol 2017; 13: 105–118.

17.

Braune

Lang

Bergmann

et al . Second line use of fingolimod is as effective as natalizumab in a German out-patient RRMS-cohort. J Neurol 2013; 260: 2981–2985.

18.

Koch-Henriksen

Magyari

Sellebjerg

et al . A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler 2017; 23: 234–241.

19.

Kalincik

Horakova

Spelman

et al . Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015; 77: 425–435.

20.

Barbin

Rousseau

Jousset

et al . Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology 2016; 86: 771–778.

21.

Baroncini

Ghezzi

Annovazzi

et al . Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler 2016; 22: 1315–1326.

22.

Swiss Federation for Common Tasks of Health Insurances. Annual report 2014. SVK 2014. www.svk.org

23.

R Core Development Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2011.

24.

Imai

King

et al . MatchIt: Nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42: 1–28.

25.

Tsivgoulis

Katsanos

Mavridis

et al . The efficacy of natalizumab versus fingolimod for patients with relapsing-remitting multiple sclerosis: A systematic review, indirect evidence from randomized placebo-controlled trials and meta-analysis of observational head-to-head trials. PLoS ONE 2016; 11: e0163296.

26.

Phillips

Giovannoni

Lublin

et al . Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: Treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011; 17: 970–979.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material